Search for:

In brief

On 17 August 2023, the Ministry of Health published the draft decree, and related technical regulations, on the “Transparent Healthcare” public register and launched a public consultation to gather comments and contributions from stakeholders, including manufacturers of health products, healthcare professionals and organizations.


Key takeaways 

In such register, the establishment of which is provided for by Article 5 of Law No. 62 of 31 May 2022 (“Sunshine Act“), the Ministry of Health will publish the communications and data relating to relationships of economic importance between manufacturing companies, healthcare professionals and organizations, as well as the sanctions imposed for the violation of the disclosure and transparency requirements laid down in the Sunshine Act.

Specifically, the draft decree regulates the requirements and procedures for the transmission by manufacturing companies of communications and data related to the above-mentioned relationships, the disclosure by the Ministry of Health of the same data as well as the timing for their publication and retention. On the other hand, the technical regulations establish the internal organization of the register, its infrastructural features and the modalities for consulting the register.

Contributions from stakeholders will be assessed by the Ministry of Health and the other competent authorities to finalize the draft decree. From the date of activation of the register, which will be announced by a notice published in the Official Journal, the deadlines for the application of the disclosure obligations introduced by the Sunshine Act will start to run.

Author

Roberto Cursano has been a lawyer in Baker McKenzie since September 2007. He focuses on healthcare law and compliance, and assists in tender procedures, the negotiation of public contracts and litigation before administrative courts. Mr. Cursano is a former administrative officer in the Italian Ministry of Health and helps clients work closely with the Italian Public Administration. He is admitted to the bar before the Italian Supreme Court and the Council of State. As well as training and tutoring in the master’s degree program on clinical trials of pharmaceutical products at the University of Rome Sapienza, Mr. Cursano regularly publishes articles and scientific contributions. He also frequently hosts and participates in seminars and presentations on pharmaceutical and administrative law matters.

Author

Francesca R. Baratta is an Associate in Baker McKenzie Rome office.

Author

Riccardo Ovidi is an Associate in Baker McKenzie Rome office.